The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2021 | The importance of regular sFLC assessment in myeloma
Uros Markovic, MD, University of Catania, Catania, Italy, discusses the importance of regular serum free light chain (sFLC) assessment for the detection of early oligosecretory/free light chain escape in myeloma patients, regardless of disease secretory status. The retrospective study analysed real-world data from 130 relapsed/refractory myeloma patients treated with at least three prior lines of therapy between 2000 and 2020. Out of 106 patients who were normosecretory at diagnosis, 18 had oligosecretory/micromolecular escape at first disease relapse and a further six patients had oligosecretory/micromolecular escape at second disease relapse. This demonstrates the need for regular sFLC monitoring in multiple myeloma patients, regardless of secretory status. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Uros Markovic, MD, discloses an affiliation with Amgen.
